Oncogenic K-Ras requires activation for enhanced activity

Oncogenic Ras mutations are widely considered to be locked in a permanent ‘On’ state and ‘constitutively active’. Yet, many healthy people have cells possessing mutant Ras without apparent harm, and in animal models mutant Ras causes transformation only after upregulation of Ras activity. Here, we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity. These data indicate that in addition to targeting K-Ras downstream effectors, interventions to reduce K-Ras activation may have important cancer-preventive value, especially in patients with oncogenic Ras mutations. As other small G proteins are regulated in a similar manner, this concept is likely to apply broadly to the entire Ras family of molecules.

[1]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[2]  W. Kabsch,et al.  The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. , 1997, Science.

[3]  J. Bos,et al.  Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras , 1997, Oncogene.

[4]  Jens T Siveke,et al.  EGF receptor is required for KRAS-induced pancreatic tumorigenesis. , 2012, Cancer cell.

[5]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[6]  B. Ji,et al.  Robust acinar cell transgene expression of CreErT via BAC recombineering , 2008, Genesis.

[7]  Xinghua Lu,et al.  Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. , 2002, Chinese medical journal.

[8]  M. Korc,et al.  Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. , 2009, Biochemical and biophysical research communications.

[9]  R. Schmid,et al.  Concomitant pancreatic activation of Kras(G12D) and Tgfa results in cystic papillary neoplasms reminiscent of human IPMN. , 2007, Cancer cell.

[10]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[11]  Y. Shiratori,et al.  Analysis of K-ras gene mutation in hyperplastic duct cells of the pancreas without pancreatic disease. , 1996, Gastroenterology.

[12]  Yan Liu,et al.  An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. , 2012, The Journal of clinical investigation.

[13]  F. Meng,et al.  K-RAS mutation in the screening, prognosis and treatment of cancer. , 2009, Biomarkers in medicine.

[14]  Ucd Building Molecular analysis to detect pancreatic ductal adenocarcinoma in high-risk groups , 2005 .

[15]  T. Jacks,et al.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. , 2001, Genes & development.

[16]  F. McCormick,et al.  Signal transduction by Ras-like GTPases: a potential target for anticancer drugs. , 1995, Gene expression.

[17]  M. Korc,et al.  Action of secretagogues on a new preparation of functionally intact, isolated pancreatic acini. , 1978, The American journal of physiology.

[18]  Z. Ronai,et al.  High frequency of K‐ras mutations in normal appearing lung tissues and sputum of patients with lung cancer , 1995, International journal of cancer.

[19]  E. Petricoin,et al.  Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. , 2003, Cancer cell.

[20]  Manuel Serrano,et al.  Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. , 2003, Cancer cell.

[21]  C. Denny,et al.  Molecular mechanisms of cancer. , 1991, The Western journal of medicine.